公开(公告)号：US20250057837A1

公开(公告)日：2025-02-20

申请号：US18935760

申请日：2024-11-04

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Tianli Wang

IPC: A61K31/498 ,  A61K31/454 ,  A61K31/7056 ,  A61K31/7072 ,  A61P31/14 ,  G06F7/00 ,  G06F16/215 ,  G06F16/23 ,  G06F16/25

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20210023012A1

公开(公告)日：2021-01-28

申请号：US16837576

申请日：2020-04-01

Applicant: AbbVie Inc.

Inventor： Wei Liu ,  Hoi Kei Lon ,  Sven Mensing ,  Jeffrey Schmidt ,  Neha Thakre ,  Thin Yu Tu

IPC: A61K9/24 ,  A61P31/14 ,  A61K38/06 ,  A61K31/454 ,  A61K9/28 ,  A61K9/20 ,  A61K9/50 ,  A61K9/48

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first type of film-coated granules which comprise 50 mg of Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second type of film-coated granules which comprise 20 mg of Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

公开(公告)号：US20180085330A1

公开(公告)日：2018-03-29

申请号：US15713137

申请日：2017-09-22

Applicant: AbbVie Inc.

Inventor： Sandeep Dutta ,  Matthew Kosloski ,  Wei Liu

IPC: A61K31/192 ,  A61K38/13 ,  A61K31/22

CPC classification number: A61K31/192 ,  A61K31/22 ,  A61K31/454 ,  A61K31/498 ,  A61K38/13 ,  A61K2300/00 ,  A61K31/7048

Abstract: This application features dose adjustment for drugs co-administered with glecaprevir and pibrentasvir.

公开(公告)号：US20170014348A1

公开(公告)日：2017-01-19

申请号：US15278645

申请日：2016-09-28

Applicant: AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

Inventor： Joerg Breitenbach ,  Salih Durak ,  Sandeep Dutta ,  Thomas Y. Kessler ,  Wei Liu ,  Friedrich W. Richter ,  Joerg Rosenberg ,  Gerd Woehrle

IPC: A61K9/28 ,  A61K31/167 ,  A61K9/00 ,  A61K31/485

CPC classification number: A61K9/28 ,  A61K9/0053 ,  A61K9/209 ,  A61K31/167 ,  A61K31/192 ,  A61K31/485 ,  A61K2300/00

Abstract: The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially confined in the core and a non-abuse relevant drug in a non-core region. These formulations have reduced potential for abuse. In the formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding. Certain embodiments of the inventions provide dosage forms that provide an initial burst of release of drug followed by a prolonged period of controllable drug release.

Abstract translation: 本申请中优选的示例性实施方案提供用于递送药物，特别是滥用药物，具有基本上限于核心的滥用相关药物和非核心区域中的非滥用相关药物的制剂和方法。 这些制剂减少了滥用的可能性。 在制剂中，优选滥用相关药物是阿片样物质，非滥用相关药物是对乙酰氨基酚或布洛芬。 更优选地，阿片样物质是氢可酮，非滥用相关镇痛药是对乙酰氨基酚。 在某些优选的实施方案中，剂型的特征在于耐溶剂萃取; 篡改，破碎或研磨。 本发明的某些实施方案提供剂型，其提供药物释放的初始爆发，随后延长药物释放时间。

公开(公告)号：US20130344143A1

公开(公告)日：2013-12-26

申请号：US13729313

申请日：2012-12-28

Applicant: AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

Inventor： Joerg Rosenberg ,  Gerd Woehrle ,  Thomas Y. Kessler ,  Joerg Breitenbach ,  Salih Durak ,  Friedrich W. Richter ,  Wei Liu ,  Sandeep Dutta

IPC: A61K9/28 ,  A61K31/167 ,  A61K31/485

CPC classification number: A61K9/28 ,  A61K9/0053 ,  A61K9/209 ,  A61K31/167 ,  A61K31/192 ,  A61K31/485 ,  A61K2300/00

Abstract: The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially confined in the core and a non-abuse relevant drug in a non-core region. These formulations have reduced potential for abuse. In the formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding. Certain embodiments of the inventions provide dosage forms that provide an initial burst of release of drug followed by a prolonged period of controllable drug release.

公开(公告)号：US11484534B2

公开(公告)日：2022-11-01

申请号：US15431906

申请日：2017-02-14

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Tianli Wang

IPC: A61K31/498 ,  A61K31/454 ,  A61K38/05 ,  A61K38/06

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20160317603A9

公开(公告)日：2016-11-03

申请号：US14676378

申请日：2015-04-01

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Thomas J. Podsadecki ,  Tianli Wang

IPC: A61K38/06 ,  A61K38/05 ,  A61K31/7056 ,  A61K31/7072

CPC classification number: A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20150283199A1

公开(公告)日：2015-10-08

申请号：US14676378

申请日：2015-04-01

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Thomas J. Podsadecki ,  Tianli Wang

IPC: A61K38/06 ,  A61K38/05 ,  A61K31/7056 ,  A61K31/7072

CPC classification number: A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract translation: 本发明具有用于治疗HCV的无干扰素治疗。 优选地，治疗超过较短的治疗持续时间，例如不超过12周。 一方面，治疗包括给具有HCV感染的受试者施用至少两种直接作用的抗病毒剂和利巴韦林，其中所述治疗持续12周，并且不包括施用干扰素，并且所述至少两种直接作用的抗病毒剂包含 a）化合物1或其药学上可接受的盐和（b）化合物2或其药学上可接受的盐。

公开(公告)号：US20240115650A1

公开(公告)日：2024-04-11

申请号：US18534967

申请日：2023-12-11

Applicant: ABBVIE INC.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Thomas J. Podsadecki ,  Tianli Wang ,  Sven Mensing

IPC: A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072 ,  A61K38/05

CPC classification number: A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072 ,  A61K38/05

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220288153A1

公开(公告)日：2022-09-15

申请号：US17484287

申请日：2021-09-24

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Thomas J. Podsadecki ,  Tianli Wang ,  Sven Mensing

IPC: A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.